#Taipei #None #MolecuLight #Healtdeva #DSWI

MolecuLight Imaging Revolutionizes Treatment and Reduces Costs

In a pioneering study conducted at Shuang-Ho Hospital in Taipei, Taiwan, MolecuLight Inc. has made significant strides in the management of deep sternal wound infections (DSWI). This innovative imaging technology has shown to not only improve patient outcomes but also to substantially lower costs associated with treatment, marking a new era in surgical applications.

Clinical Study Overview

The recent clinical trial, titled Effects of Adjunctive Hyperbaric Oxygen Therapy and Real-Time Fluorescent Imaging on Deep Sternal Wound Infection: A Retrospective Study, has been published in the Journal of Wound Care in 2025. This study highlights the advantages of integrating MolecuLight’s iX® imaging into the treatment protocols for DSWI. Key findings unveil various transformative impacts including quicker resolution rates of infections, dramatically reduced antibiotic usage, and shorter hospital stays.

Key Outcomes from the Trial

1. Enhanced Infection Control

One of the most notable outcomes revealed is the vastly improved infection management through real-time imaging. Patients under MolecuLight’s guidance exhibited a 26-fold increase in the likelihood of normal white blood cell counts within seven days. Moreover, the rate of normalization of C-reactive protein levels saw a remarkable sevenfold improvement over the conventional hyperbaric oxygen therapies.

2. Reduction in Antibiotic Usage

The study reported that patients treated with MolecuLight required antibiotics for significantly fewer days — 22 days compared to 29.5 days for the control group. This reduction led to a notable reduction in antibiotic costs, translating to savings of approximately $1,070 in treatment expenses.

3. Accelerated Healing and Healthcare System Relief

Patients receiving MolecuLight treatment enjoyed a 70% reduction in intensive care unit stays, averaging just three days instead of ten. Furthermore, their wound healing was expedited by 20%, achieving full recovery in 40 days, versus 50 days for the standard care protocol.

4. Minimized Risk of Complications

The use of MolecuLight imaging was linked to an 82% decrease in the probability of hospital readmission due to wound re-infections, and an astonishing 86% reduction in the risk of recurrent osteomyelitis, underscoring its critical role in long-term patient welfare.

5. Improved Efficiency in Debridement Procedures

The study also emphasized the effectiveness of MolecuLight in guiding more precise debridement efforts, which is pivotal for effective wound treatment and infection control.

Expert Opinions

Dr. Shun-Cheng Chang, one of the study’s authors, emphasized the educational benefits of MolecuLight, stating, “The ability to visualize bacterial presence in real-time allows us to teach young doctors vital infection control principles and improve their intraoperative assessments.”

Wei-Pin Hsieh, CEO of Healtdeva Company Ltd., expressed their commitment to integrating this advanced imaging technology into Taiwan’s health system, citing its potential to enhance diagnostic efficiency in complex wound management.

MolecuLight's CEO, Anil Amlani, reiterated the study’s significance, highlighting its clinical and economic value not only in chronic wound care but also in critical surgical applications. He stated, “This technology provides essential real-time insights that empower clinicians to make informed decisions, ultimately improving patient outcomes while alleviating the burden of surgical complications.”

Future Directions

The results from this study mark a pivotal step regarding the broader applicability of MolecuLight technology in surgical settings, helping clinicians optimize their strategies for managing complex cases effectively. As the medical landscape continues to evolve with technological advancements, the shift towards integrating innovative tools such as MolecuLight into clinical practice is essential for enhancing patient care and health system efficiency.

In conclusion, this groundbreaking study presents compelling evidence supporting the expanded usage of MolecuLight’s technology, heralding a promising future for patients suffering from deep sternal wound infections and beyond.